Information Provided By:
Fly News Breaks for March 12, 2019
ZFGN
Mar 12, 2019 | 13:55 EDT
JMP Securities analyst Jason Butler acknowledged that the "roadblock" for Zafgen's potential Prader Willi syndrome candidate ZGN-1258 is disappointing, but said he does not believe that it will impact the path forward for ZGN-1061. After having removed ZGN-1258 from his valuation, Butler cut his price target on Zafgen shares to $8 from $17, though he keeps an Outperform rating on the stock, stating that progress remains on track to address the clinical hold for ZGN-1061.
News For ZFGN From the Last 2 Days
There are no results for your query ZFGN